Catatan sumber primer
PenentuPerubahan registri uji klinis
SELLAS: Uji coba REGAL Phase 3 GPS AML mencapai 78/80 kejadian
Uji coba REGAL Phase 3 GPS dalam AML telah mencapai 78 dari 80 kejadian yang telah ditentukan sebelumnya yang diperlukan untuk analisis akhir. Perusahaan tetap blinded terhadap hasil dan akan melakukan analisis akhir setelah kejadian ke-80 terjadi, memicu database lock dan topline disclosure.
Fakta utama
- Diajukan
- 12 Mei 2026, 20.07
- Peristiwa
- Perubahan registri uji klinis
- Arah
- Netral
- Perusahaan
SLSSELLAS Life Sciences- Aset
- galinpepimut-S
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
- peristiwa tercapai
- 78
- peristiwa diperlukan
- 80
Kutipan sumber
EX-99.1 2 sls-202605128xkexhibit991.htm EX-99.1 Document Exhibit 99.1 SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update – Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes – – Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80 th Event – – Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises – NEW YORK, NY May 12, 2026 -- SELLAS Li